Drugs / BFB759
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07105488 | Jul 2025 → Feb 2027 expected | atopic eczema | Bluefin Biomedicine, Inc. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07287644 | Nov 2025 → Aug 2027 expected | hidradenitis suppurativa | Bluefin Biomedicine, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BFB759 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287644 ↗ |
| Action | Inhibit | “inhibits multiple pro-inflammatory cytokines” NCT07287644 ↗ |
| Modality | Monoclonal antibody | “BFB759 is a human mAb” NCT07105488 ↗ |